DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Aztreonam (CAYSTON®)

To Patients

To Patients

Therapeutic Approach

Anti-Infective

Inhaled aztreonam (CAYSTON®)is an antibiotic that has been approved for people with CF who are chronically infected with Pseudomonas aeruginosa.

Status

A Phase 3 clinical trial demonstrated improvement in lung function and respiratory symptoms for those infected with Pseudomas aeruginosa. CAYSTON® received FDA approval in 2010. 

CAYSTON® is no longer available in Australia.

Sponsor

The program was sponsored in the US by Gilead Sciences, Inc. and partially funded by Cystic Fibrosis Foundation Therapeutics (CFTT). It was conducted within CFTT's Therapeutics Development Network.

Contact us about Aztreonam (CAYSTON®) >